Conflicts of interest CL has received consultancy fees from GSK & SPMSD. JR has received speaker’s fees, sponsorship to attend conferences and research grants from Abbott, Boehringer Ingelheim, Gilead, GSK, Roche, BMS, MSD, Bayer and Tibotec.
2012 European guideline for the management of anogenital warts
Version of Record online: 12 MAR 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 3, pages e263–e270, March 2013
How to Cite
Lacey, C.J.N., Woodhall, S.C., Wikstrom, A. and Ross, J. (2013), 2012 European guideline for the management of anogenital warts. Journal of the European Academy of Dermatology and Venereology, 27: e263–e270. doi: 10.1111/j.1468-3083.2012.04493.x
Funding sources None declared.
This guideline has been produced on behalf of the following organizations: the European Branch of the International Union against Sexually Transmitted Infections (IUSTI Europe); the European Dermatology Federation (EDF); the Union of European Medical Specialists (UEMS).
- Issue online: 18 FEB 2013
- Version of Record online: 12 MAR 2012
- Received: 20 September 2011; Accepted: 1 February 2012
Vol. 27, Issue 10, 1327, Version of Record online: 20 SEP 2013
Background Although new HPV vaccines have been developed and are in the process of implementation, anogenital warts remain a very frequent problem in clinical practice.
Objective We wished to update previously published European guidelines for the management of anogenital warts.
Methods We performed a systematic review of randomized controlled trials for anogenital warts. The primary data were analyzed and collated, and the findings were formulated within the structure of a clinical guideline. The IUSTI Europe Editorial Board reviewed the draft guideline which was also posted on the web for comments which we incorporated into the final version of the guideline.
Results The data confirm that only surgical therapies have primary clearance rates approaching 100%. Recurrences, including new lesions at previously treated or new sites, occur after all therapies, and rates are often 20–30% or more. All therapies are associated with local skin reactions including itching, burning, erosions and pain.
Conclusions Physicians treating patients with genital warts should develop their own treatment algorithms which include local practice and recommendations. Such patient level management protocols should incorporate medical review of cases at least every 4 weeks, with switching of treatments if an inadequate response is observed. First episode patients should be offered sexually transmitted disease screening. Management should include partner notification and health promotion.